1. The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages.
- Author
-
Chu LH, Indramohan M, Ratsimandresy RA, Gangopadhyay A, Morris EP, Monack DM, Dorfleutner A, and Stehlik C
- Subjects
- Animals, Caspases genetics, Caspases immunology, Caspases, Initiator, Cells, Cultured, Female, Humans, Inflammasomes immunology, Interleukin-1beta genetics, Interleukin-1beta immunology, Lipopolysaccharides adverse effects, Lipopolysaccharides immunology, Macrophages immunology, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, NLR Family, Pyrin Domain-Containing 3 Protein genetics, NLR Family, Pyrin Domain-Containing 3 Protein immunology, Shock, Septic genetics, Shock, Septic immunology, Anti-Inflammatory Agents administration & dosage, Inflammasomes drug effects, Macrophages drug effects, Phosphatidylcholines administration & dosage, Shock, Septic prevention & control
- Abstract
Lipopolysaccharide (LPS) of Gram-negative bacteria can elicit a strong immune response. Although extracellular LPS is sensed by TLR4 at the cell surface and triggers a transcriptional response, cytosolic LPS binds and activates non-canonical inflammasome caspases, resulting in pyroptotic cell death, as well as canonical NLRP3 inflammasome-dependent cytokine release. Contrary to the highly regulated multiprotein platform required for caspase-1 activation in the canonical inflammasomes, the non-canonical mouse caspase-11 and the orthologous human caspase-4 function simultaneously as innate sensors and effectors, and their regulation is unclear. Here we show that the oxidized phospholipid 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC) inhibits the non-canonical inflammasome in macrophages, but not in dendritic cells. Aside from a TLR4 antagonistic role, oxPAPC binds directly to caspase-4 and caspase-11, competes with LPS binding, and consequently inhibits LPS-induced pyroptosis, IL-1β release and septic shock. Therefore, oxPAPC and its derivatives might provide a basis for therapies that target non-canonical inflammasomes during Gram-negative bacterial sepsis.
- Published
- 2018
- Full Text
- View/download PDF